Executive Director, Biologics DMPK & Translational Sciences

Executive Director, Biologics DMPK & Translational Sciences

Odyssey Therapeutics is propelling drug development beyond what is now possible to deliver medicines that address critical needs of patients with inflammatory and immunology diseases. We achieve unprecedented speed and efficiency by bringing together a target-centric approach, a toolbox of cutting-edge technologies, and a team of accomplished, world-class drug hunters. By reimagining the drug development process, we are creating a deep and broad drug pipeline that holds the potential to transform human health.

The opportunity:

The Executive Director, Biologics DMPK & Translational Sciences will provide enterprise-wide technical and scientific leadership for the discovery-to-development transition of Odyssey's biologics portfolio, with ultimate accountability for the strategy, organization, and execution of biologics DMPK (drug metabolism and pharmacokinetics) and translational sciences. Reporting to the SVP, Nonclinical Development and serving as a key member of the Nonclinical Development leadership team, this individual will partner closely with Protein Therapeutics, Discovery, Nonclinical Safety Assessment, Biologics CMC, Regulatory Affairs, and Clinical Development, and will represent biologics DMPK and translational strategy to senior leadership and governance forums as candidates advance toward IND-ready, clinically de-risked assets.

This is a high-visibility leadership role for an accomplished scientific leader who thrives in a fast-moving, multi-modality environment and wants to build and scale the organization, capabilities, and strategic influence of biologics development as Odyssey grows its biologics portfolio.

Your primary objectives will be:

• Lead the discovery-to-nonclinical development transition strategy for Odyssey's biologics portfolio, ensuring candidates are advanced with the right develop ability, PK/PD, and translational data packages to support confident candidate nomination and IND filings.
• Define and own the biologics DMPK strategy across the portfolio, including in vitro and in vivo PK characterization, target-mediated drug disposition assessment, immunogenicity/anti-drug-antibody (ADA) impact evaluation, and bioanalytical method strategy for large molecules.
• Drive translational science and PK/PD modeling to answer critical development questions, establish exposure–response relationships, and generate robust first-in-human dose projections and biomarker strategies.
• Serve as the most senior biologics development subject-matter expert and a trusted advisor to executive leadership and governance bodies, influencing molecule design, candidate selection, and program direction through expert interpretation of DMPK and translational data.
• Partner with Discovery and Protein Therapeutics to embed develop ability and PK considerations into early molecule engineering and lead optimization for fusion proteins, Fc fusions, and antibody-based modalities.
• Work closely and in partnership with preclinical toxicology to design and execute DRF and GLP toxicology program.
• Design, oversee, and interpret nonclinical PK, pharmacology, and IND-enabling studies, including coordination of internal work and external CROs to ensure high-quality, on-time, regulatory-compliant deliverables.
• Own authorship and review of DMPK and translational sections of regulatory documents (IND, IB, briefing documents), and lead health authority interactions on DMPK and translational matters.
• Build, mentor, and scale a high-performing biologics development and DMPK organization — including people managers and senior scientists — and own the function's strategy, budget, and resourcing, establishing fit-for-purpose processes, capabilities, and ways of working as Odyssey grows.
• Represent biologics DMPK and translational sciences in business development and licensing diligence, scientific advisory board interactions, and other external partnerships, providing executive-level scientific input to portfolio and investment decisions.
• Stay current with advances in biologics DMPK, translational science, and regulatory expectations, bringing innovative and efficient approaches to the portfolio.

About you:

• Ph.D. (or equivalent) in pharmacokinetics, pharmacology, biochemistry, pharmaceutical sciences, or a related discipline.
• A minimum of 15 years of biopharmaceutical industry experience, with a substantial portion focused on the PK/DMPK and translational characterization of biologics (e.g., monoclonal…